GetTopicDetailResponse(id=51c0e3164b, topicName=FDA授予快速通道指定, introduction=FDA授予快速通道指定, content=null, image=null, comments=4, allHits=1010, url=https://h5.medsci.cn/topic?id=7316, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=102462, tagList=[TagDto(tagId=102462, tagName=FDA授予快速通道指定)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1993730, encodeId=8c1e1993e30a9, content=<a href='/topic/show?id=51c0e3164b' target=_blank style='color:#2F92EE;'>#FDA授予快速通道指定#</a>, objectTitle=Blaze Bioscience的光學(xué)成像劑BLZ-100用于"點(diǎn)亮"兒童中樞神經(jīng)系統(tǒng)腫瘤，獲FDA授予快速通道指定, objectType=article, longId=191725, objectId=4cf9191e258a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cf9191e258a, replyNumber=0, likeNumber=105, createdTime=2021-03-23, rootId=0, userName=yige2004, userId=66962500501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cf9191e258a, moduleTitle=Blaze Bioscience的光學(xué)成像劑BLZ-100用于"點(diǎn)亮"兒童中樞神經(jīng)系統(tǒng)腫瘤，獲FDA授予快速通道指定, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=4cf9191e258a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1993732, encodeId=64e91993e32ce, content=<a href='/topic/show?id=51c0e3164b' target=_blank style='color:#2F92EE;'>#FDA授予快速通道指定#</a>, objectTitle=和記黃埔的Surufatinib獲得FDA授予快速通道指定，用于治療胰腺和非胰腺神經(jīng)內(nèi)分泌腫瘤, objectType=article, longId=192484, objectId=fb0c19248469, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb0c19248469, replyNumber=0, likeNumber=91, createdTime=2020-05-06, rootId=0, userName=yige2004, userId=66962500501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb0c19248469, moduleTitle=和記黃埔的Surufatinib獲得FDA授予快速通道指定，用于治療胰腺和非胰腺神經(jīng)內(nèi)分泌腫瘤, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=fb0c19248469)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1993731, encodeId=23c71993e31f7, content=<a href='/topic/show?id=51c0e3164b' target=_blank style='color:#2F92EE;'>#FDA授予快速通道指定#</a>, objectTitle=非阿片類鎮(zhèn)痛藥EC5026治療神經(jīng)性疼痛：獲得FDA授予快速通道指定, objectType=article, longId=192008, objectId=3c4019200808, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c4019200808, replyNumber=0, likeNumber=86, createdTime=2020-04-29, rootId=0, userName=yige2004, userId=66962500501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c4019200808, moduleTitle=非阿片類鎮(zhèn)痛藥EC5026治療神經(jīng)性疼痛：獲得FDA授予快速通道指定, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=3c4019200808)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1993729, encodeId=15e31993e29d1, content=<a href='/topic/show?id=51c0e3164b' target=_blank style='color:#2F92EE;'>#FDA授予快速通道指定#</a>, objectTitle=Immunocore的tebentafusp治療轉(zhuǎn)移性葡萄膜黑色素瘤被FDA授予快速通道指定, objectType=article, longId=163663, objectId=4f8916366308, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f8916366308, replyNumber=0, likeNumber=79, createdTime=2019-06-15, rootId=0, userName=yige2004, userId=66962500501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f8916366308, moduleTitle=Immunocore的tebentafusp治療轉(zhuǎn)移性葡萄膜黑色素瘤被FDA授予快速通道指定, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=4f8916366308)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
